邁克生物(300463.SZ):2019年淨利預增15%-25%
格隆匯1月20日丨邁克生物(300463.SZ)披露2019年度業績預告,公司預計2019年1-12月歸屬於上市公司股東的淨利潤為約5.12億元-約5.56億元,同比增長15%-25%。業績變動原因如下:
根據企業戰略規劃和市場發展態勢,公司以自主產品為核心不斷提升經營能力和管理效率,報告期內,隨着公司在各研發平台持續投入和能力積累,多項新產品穩步上市,公司積極展開市場推廣和銷售渠道建設工作,自主產品銷售收入保持穩健增長,盈利水平有所提升;同時公司外延併購和代理產品的增長同比下降,運營效率和財務狀況持續改善,2019年度公司經營業績呈現穩步向上的態勢。
報告期內,預計非經常性損益對淨利潤的影響為1700萬元左右,主要系政府補助。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.